 |
嘉興行健生物科技有限公司
主營產(chǎn)品： 人穩(wěn)定型骨鈣素（1-43/49）ELIsA試劑盒,人酶免試劑盒,大小鼠酶免試劑盒,猴酶免試劑盒,牛酶免試劑盒 |
會員1.png)
|
嘉興行健生物科技有限公司
主營產(chǎn)品： 人穩(wěn)定型骨鈣素（1-43/49）ELIsA試劑盒,人酶免試劑盒,大小鼠酶免試劑盒,猴酶免試劑盒,牛酶免試劑盒 |
| 參考價 | 面議 |
人胎球蛋白A（Fetuin-A）酶免試劑盒
美國*
【型號】 KT-800
【預(yù)期用途】
這個ELISA試劑盒是用來對血清、血漿、細(xì)胞培養(yǎng)上清液、組織提取液以及尿液中的人胎球蛋白A也叫做α-2-Heremans-Schmid糖蛋白（α2–Heremans- Schmid glycoprotein, AHSG）的濃度進(jìn)行定量檢測?？梢酝ㄟ^對胎球蛋白A的檢測來診斷某些癌癥和血清蛋白的基因遺傳缺陷。血清胎球蛋白A下降是體內(nèi)炎癥的重要指標(biāo)，并與冠狀動脈硬化和心臟鈣化密切相關(guān)；尿液胎球蛋白A與腎功能相關(guān)。該胎球蛋白酶免試劑盒僅供實驗研究使用。
【生理學(xué)簡介】
胎球蛋白A也叫做α-2-Heremans-Schmid糖蛋白，它的分子量是59kDa，擁有兩個氨基末端半胱胺酸蛋白酶抑制因子和一個較小的羧基末端區(qū)域。胎球蛋白A通過肝臟合成，分泌到血液中。一般來說，成人血液中胎球蛋白A的濃度范圍為0.5-1.0g/L。在胎兒體內(nèi)，血清中胎球蛋白A呈現(xiàn)出高濃度。它會參與蛋白酶抑制活動以及鈣代謝和骨生成的相關(guān)活動。胎球蛋白A在骨骼和牙齒中積累，是生物學(xué)上的非膠原骨蛋白成分的主要部分。經(jīng)研究證明，胎球蛋白A會阻止鈣沉淀，是循環(huán)過程中的zui主要的鈣化抑制劑。zui近的研究表明，尿毒癥、血液透析患者的胎球蛋白A的濃度比正常健康人的低。腎功能衰竭患者的胎球蛋白A濃度低與心血管死亡率增高相關(guān)。另一方面，老年血清胎球蛋白A增高，更易患糖尿病，它是一個*的胰島素靈敏度下降指標(biāo)。甚至，有科研結(jié)果表明高胎球蛋白A濃度可以作為心血管疾病患者的一個獨(dú)立指標(biāo)。
【檢驗原理】
這個ELISA的設(shè)計，研發(fā)和生產(chǎn)的目的是對血清中人胎球蛋白A進(jìn)行定量檢驗。該試劑盒是基于運(yùn)用兩種特定羊抗人胎球蛋白A多抗與人胎球蛋白A的不同抗原表位結(jié)合的“雙位點(diǎn)夾心”技術(shù)。
將標(biāo)準(zhǔn)品、質(zhì)控品、和含胎球蛋白A的預(yù)稀釋的的病人血清樣本加入到高度親和性的羊抗人胎球蛋白A抗體包被的微孔板中。經(jīng)過*個保溫孵育期后，人胎球蛋白A被微孔板內(nèi)壁的抗體吸附住，而各個孔中的游離蛋白質(zhì)被沖走。隨后，HRP標(biāo)記的多抗抗人胎球蛋白A抗體加入到各個孔中，形成了“捕捉抗體-人胎球蛋白A-HRP標(biāo)記示蹤抗體”的“雙位點(diǎn)夾心”結(jié)構(gòu)。游離的示蹤抗體在隨后的清洗過程中被沖走。HRP標(biāo)記的示蹤抗體被吸附到微孔板的內(nèi)壁，在3,3',5,5'-四甲基聯(lián)苯胺（TMB）和過氧化氫的混合基質(zhì)溶液中經(jīng)過一段時間的反應(yīng)，測量吸光度。微孔板內(nèi)壁的胎球蛋白A與示蹤抗體連結(jié)的酶活性與樣本中胎球蛋白A的濃度直接成正比例。根據(jù)標(biāo)準(zhǔn)品中不同的胎球蛋白A的濃度的吸光度，按照“點(diǎn)到點(diǎn)”或者“體積比例”繪制標(biāo)準(zhǔn)曲線，待測樣品中胎球蛋白A的濃度可以直接從標(biāo)準(zhǔn)曲線按測量到的吸光度得到。
【組成成分】
1. 胎球蛋白A抗體包被的微孔板：1塊×96個
2. 胎球蛋白A示蹤抗體：1瓶×0.6mL
3. 示蹤抗體稀釋液：1瓶×12mL
4. 胎球蛋白A檢測濃縮緩沖液：1瓶×11mL
5. ELISA 濃縮洗滌液，30X ：1瓶×20mL
6. ELISA HRP基質(zhì)：1瓶×12mL
7. ELISA終止液：1瓶×12mL
8. 胎球蛋白A標(biāo)準(zhǔn)品：5瓶
9. 胎球蛋白A質(zhì)控品：2瓶
【應(yīng)用本試劑盒已發(fā)表的文獻(xiàn)】
1. Stenvinkel P, Wang K, Qureshi AR, Axelsson J, Pecoits-Filho R, Gao P, Barany P, Lindholm B, Jogestrand T, Heimbürger O, Holmes C, Schalling M, Nordfors L. Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. Kidney Int. 2005 Jun;67（6）:2383-92.
2. Wang AY, Woo J, Lam CW, Wang M, Chan IH, Gao P, Lui SF, Li PK, Sanderson JE. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant. 2005 Aug;20（8）:1676-85.
3. Sato H, Kazama JJ, Wada Y, Kuroda T, Narita I, Gejyo F, Gao P, Yamashita H. Decreased levels of circulating alpha2-Heremans-Schmid glycoprotein/Fetuin-A （AHSG） in patients with rheumatoid arthritis. Intern Med. 2007;46（20）:1685-91. Epub 2007 Oct 15.
4. Lehtinen AB, Burdon KP, Lewis JP, Langefeld CD, Ziegler JT, Rich SS, Register TC, Carr JJ, Freedman BI, Bowden DW. Association of alpha2-Heremans-Schmid glycoprotein polymorphisms with subclinical atherosclerosis. J Clin Endocrinol Metab. 2007 Jan;92（1）:345-52. Epub 2006 Oct 24
5. Lim P, Collet JP, Moutereau S, Guigui N, Mitchell-Heggs L, Loric S, Bernard M, Benhamed S, Montalescot G, Randé JL, Guéret P. Fetuin-A is an independent predictor of death after ST-elevation myocardial infarction. Clin Chem. 2007 Oct;53（10）:1835-40. Epub 2007 Aug 16
6. Ix JH, Wassel CL, Kanaya AM, Vittinghoff E, Johnson KC, Koster A, Cauley JA, Harris TB, Cummings SR, Shlipak MG; Health ABC Study. Fetuin-A and incident diabetes mellitus in older persons. JAMA. 2008 Jul 9;300（2）:182-8.
7. Ix JH, Wassel CL, Bauer DC, Toroian D, Tylavsky FA, Cauley JA, Harris TB, Price PA, Cummings SR, Shlipak MG; for the Health ABC Study. Fetuin-A and Bone Mineral Density in Older Persons: The Health Aging and Body Composition （Health ABC） Study. J Bone Miner Res. 2008 Nov 18.
8. Giulia Bivona, Chiara Bellia, Antonietta Caruso, Daniela Butera, Bruna Lo Sasso, Patrizia Altavilla, Rosa C. Carollo, Gaia Chiarello andMarcello Ciaccio. Low Serum Fetuin A Levels and Cardiovascular Events in End-Stage Renal Disease （ESRD） Patients. Research Journal of Medical Sciences 2 （4）: 200-202, 2008
9. Mario Cozzolinoa, Andrea Galassia, Maria Luisa Biondib, Olivia Turrib, Sergio Papagnic, Nicola Mongellic, Luigi Civitac, Maurizio Gallienia, Diego Brancaccioa Serum Fetuin-A Levels Link Inflammation and Cardiovascular Calcification in Hemodialysis Patients. Am J Nephrol 2006;26:423-429
10. G. Metry, P. Stenvinkel, A. R. Qureshi, J. J. Carrero, M. I. Yilmaz, P. Bárány, S. Snaedal, O. Heimbürger, B. Lindholm and M. E. Suliman Low serum fetuin-A concentration predicts poor outcome only in the presence of inflammation in prevalent haemodialysis patients. European Journal of Clinical Investigation 2008;38（11）:804 - 811
11. Doris Hendig, Veronika Schulz, Marius Arndt, Christiane Szliska, Knut Kleesiek, and Christian Go¨ tting1. Role of Serum Fetuin-A, a Major Inhibitor of Systemic Calcification, in Pseudoxanthoma Elasticum. Clin Chem 2006;52:227-234
12. G. Marhaug, V. Shah, R. Shroff, H. Varsani, L. R. Wedderburn, C. A. Pilkington and P. A. Brogan. Age-dependent inhibition of ectopic calcification: a possible role for fetuin-A and osteopontin in patients with juvenile dermatomyositis with calcinosis. Rheumatology 2008 47（7）:1031-1037
13. Marcello Ciaccio, et al. Changes in serum fetuin-A and inflammatory markers levels in end-stage renal disease （ESRD）: effect of a single session haemodialysis. Clin Chem Lab Med 2008;46:212–214
14. J. J. Carrero, P. Stenvinkel, B. Fellström, A. R. Qureshi, K. Lamb , O. Heimbürger, P. Bárány, K. Radhakrishnan, B. Lindholm, I. Soveri, L. Nordfors & P. G. Shiels. omere attrition is associated with inflammation, low fetuin-A levels and high mortality in prevalent haemodialysis patients. Journal of Internal Medicine 2007; 263（3）:302 – 312
15. C . Fiore , G . Celotta , G . Politi , L . Di Pino , Z . Casli , R . Mangiafico , S . Signorelli , P . Pennisi . Association of high alpha2-Heremans–Schmid glycoprotein/fetuin concentration in serum and intima-media thickness in patients with atherosclerotic vascular disease and low bone mass. Atherosclerosis 2007;195:110-115.
16. Sandro Mazzaferro, Marzia Pasquali, Francesco Pugliese, Giusi Barresi, Iacopo Carbone, Marco Francone, Daniela Sardella, Franco Taggi. Serum Levels of Calcification Inhibition Proteins and Coronary Artery Calcium Score: Comparison between Transplantation and Dialysis. Am J Nephrol 2007;27:75-83.
Human Fetuin-A ELISA Kit
Catalog Number: KT-800
This ELISA （enzyme-linked immunosorbent assay） kit is intended for the quantitative determination of human Fetuin-A, also known as alpha-2-HS glycoprotein （AHSG）, in serum, plasma, cell culture supernatant, tissue extraction and urine. The measurement of Fetuin-A in serum or plasma aids in the diagnosis of some cancers and genetically inherited deficiencies of this serum protein. This Fetuin-A ELISA kit is for laboratory professional use.
Fetuin-A, also known as alpha-2-HS glycoprotein, is a 59 kDa glycoprotein that consists of two amino-terminal cystatin domains and a smaller carboxyl-terminal domain. Fetuin-A is synthesized by the liver and secreted into blood stream, where its concentration in adult mammals ranges from 0.5 – 1.0 g/L. Fetuin-A occurs in high serum concentration during fetal life and involves in protease inhibitory activities and development-associated regulation of calcium metabolism and osteogenesis. It accumulates in bones and teeth as a major fraction of noncollagenous bone proteins Biologically, studies have demonstrated that Fetuin-A is the major calcification inhibitor found in circulation, where it interferes with calcium salt precipitation. Recent study has indicated that Fetuin-A level drops in uremic patients on hemodialysis in comparison to normal healthy controls. The low Fetuin-A level in patients with chronic kidney failure strongly associates with a higher cardiovascular mortality. On the other hand, it is demonstrated that a higher than normal serum Fetuin-A in older population associates incident diabetes, which is independent from other markers of insulin resistance. Further, a higher Fetuin-A level may be an independent risk marker of patients with for cardiovascular diseases.
This ELISA is designed, developed and produced for the quantitative measurement of human Fetuin-A in serum samples. The assay utilizes the two-site “sandwich” technique with two selected goat anti-human Fetuin-A polyclonal antibodies that bind to different epitopes of human Fetuin-A.
Assay standards, controls and prediluted patient serum samples containing human Fetuin-A is added to microtiter wells of microplate that was coated with a high affinity polyclonal goat anti-human Fetuin-A antibody. After the first incubation period, the antibody on the wall of microtiter well captures human Fetuin-A in the sample and unbound proteins in each microtiter well is washed away. Then a horseradish peroxidase （HRP） conjugated polyclonal anti-human Fetuin-A antibody is added to each microtiter well and a “sandwich” of “capture antibody - human Fetuin-A - HRP conjugated tracer antibody” is formed. The unbound tracer antibody is removed in the subsequent washing step. HRP conjugated tracer antibody bound to the well is then incubated with a substrate solution in a timed reaction and then measured in a spectrophotometric microplate reader. The enzymatic activity of the tracer antibody bound to the Fetuin-A on the wall of the microtiter well is directly proportional to the amount of Fetuin-A in the sample. A standard curve is generated by plotting the absorbance versus the respective human Fetuin-A concentration for each standard on point-to-point or cubical scales. The concentration of human Fetuin-A in test samples is determined directly from this standard curve.
REAGENTS: Preparation
1. Fetuin-A Antibody Coated Microplate ：96 wells
2. Fetuin-A Tracer Antibody ：1vial× 0.6 mL
3. Tracer Antibody Diluent：1vial× 12mL
4. Fetuin-A Assay Buffer Concentrate ：1vial× 11mL
5. ELISA Wash Concentrate，30X：1 bottle× 20mL
6. ELISA HRP Substrate ：1 bottle× 12mL
7. ELISA Stop Solution：1 bottle× 12mL
8. Fetuin-A Standards ：5 vials
9. Fetuin-A Controls ：2 vials
